Skip to main content
Amylyx Pharmaceuticals, Inc. logo

Amylyx Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · AMLX ISIN · US0321085088 US Manufacturing
Open in API
Filings indexed 383 across all filing types
Latest filing 2023-08-10 Interim / Quarterly Rep…
Country US United States of America
Listing US AMLX

About Amylyx Pharmaceuticals, Inc.

https://www.amylyx.com/

Amylyx Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative diseases and other conditions with high unmet medical needs. The company's primary therapeutic candidate was AMX0035 for the treatment of amyotrophic lateral sclerosis (ALS). In April 2024, following the results of a Phase 3 clinical trial, Amylyx announced it would voluntarily withdraw the marketing authorizations for AMX0035 in the U.S. and Canada. The company is advancing a pipeline of other investigational therapies, utilizing a modality-agnostic approach to match treatments to diseases based on mechanistic rationale and rigorous scientific data.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q2 2023
2023-08-10 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 10, 2023, by Amylyx Pharmaceuticals, Inc. It announces the issuance of a press release with financial results for the fiscal quarter ended June 30, 2023. The document itself does not contain detailed financial statements or substantive financial data but rather references the press release as an exhibit. The length is 3503 characters, which is relatively short and consistent with an announcement rather than a full report. According to the 'Menu vs Meal' rule, this is an announcement of financial results, not the full earnings release or quarterly report itself. Therefore, the appropriate classification is Earnings Release (ER), as it is the initial announcement of quarterly financial results.
2023-08-10 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated July 26, 2023, by Amylyx Pharmaceuticals, Inc. It reports that the company hosted a conference call with investors and analysts to discuss clinical trial work and provides an overview of the Orion Phase 3 clinical trial. It mentions that selected slides from the investor presentation used during the call are attached as an exhibit. The document is primarily an announcement of a conference call and includes an investor presentation as an exhibit. The text does not contain full financial statements or detailed financial analysis but rather a summary of the event and reference to the presentation. According to the filing definitions, a document reporting a conference call with attached presentation slides is best classified as a Call Transcript (CT) if it contains the full transcript, or Investor Presentation (IP) if it is primarily the presentation. Since the text states the slides are attached and the call was hosted, this is a Current Report announcing the call and presentation. The content is consistent with an Investor Presentation (IP) filing type, as the presentation slides are the main substantive content. The document length is 3117 characters, which is short but includes the presentation slides as an exhibit, indicating the presentation is part of the filing. Therefore, the best classification is Investor Presentation (IP).
2023-07-26 English
4
Director's Dealing
2023-07-14 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated June 23, 2023. It reports a specific event: the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a negative opinion on a marketing authorization application. The document includes a press release as an exhibit. There are no financial statements or detailed financial data presented. The length is 3279 characters, which is relatively short and consistent with an event announcement rather than a full financial report. The document is not an earnings release, annual report, or interim report. It is a regulatory filing reporting a material event. Therefore, the appropriate classification is Regulatory Filings (RNS).
2023-06-23 English
FORM 4 SUBMISSION
Director's Dealing
2023-06-13 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.